Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

IMS 2023 | Risk of infection in patients with multiple myeloma treated with bispecific antibodies

Samer Al Hadidi, MD, University of Arkansas for Medical Sciences, Little Rock, AR, discusses the results of a recent analysis evaluating the risk of infections associated with the use of bispecific antibodies (BsAbs) in multiple myeloma. The results suggest that infections and higher grade neutropenia occur more frequently with BCMA-targeting BsAbs. Prophylactic measures with acyclovir and updating vaccination records are advised to mitigate these risks. This interview took place at the 20th International Myeloma Society (IMS) Annual Meeting, held in Athens, Greece.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.